Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE, a global pharmaceutical company, to advance solutions in multiple therapeutic areas.
The two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients.
This collaboration will utilize Abu Dhabi’s genomics expertise as well as its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include the exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience.
The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT – a form of precision nuclear medicine that may recognize and treat disease in patients with advanced cancers – with key stakeholders, including policymakers, healthcare professionals, and patient organizations.
Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH said that, “Novartis has been a long-standing partner to the Department of Health, and we are proud to explore these new areas of opportunity to collaborate for the ultimate benefit of patients in the region and beyond. We believe that this partnership will allow us to further accelerate the field of personalized and precision medicine across important therapeutic areas. As we continue to establish Abu Dhabi as a hub for global life science and a center for innovative research, we are excited to work in synergy with our strategic partners and combine our expertise in the pursuit of common goals.”
Under the MoU, Novartis will also work with DoH to explore innovative solutions for local and regional health needs. This will include supporting the Emirati Genome Program by collaborating to raise awareness of genetic and rare diseases for the benefit of patients in Abu Dhabi and the broader region. The final focus area is supporting the further improvement of the Health Technology Assessment through facilitated partnership and shared best practices.
Mohamed Ezz Eldin Head of Gulf countries for Novartis, stated that, “This partnership represents a significant milestone in advancing research and innovation in healthcare, particularly in the fields of oncology, cardiovascular diseases, and neuroscience. Novartis is committed to supporting the development of clinical research capabilities in Abu Dhabi, generating real-world evidence, and raising awareness about radioligand therapy. We look forward to working closely with the Department of Health – Abu Dhabi to drive innovation and enhance the Health Technology Assessment capabilities in the region. Our goal is to contribute to personalized and precision medicine, ultimately improving patient outcomes.”
